BSX
Boston Scientific Corporation
Healthcare · Medical Devices · United States · Stock
Score Breakdown
Scored for Aggressive Growth profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The combined momentum and growth sub-scores (18.0 and 17.5 respectively) contribute 35.5 of the 60.3 total model points, anchoring the score firmly in the research candidate range on the strength of filing-derived operational improvement data.
- A financial health sub-score of 16.0/20 provides meaningful support to the composite score, reflecting that balance sheet size, interest coverage, and leverage ratios in the FY 2025 10-K remain within the model's acceptable thresholds.
- The 9.0/10 confidence rating, achieved with 9 of 10 core metrics successfully mapped from EDGAR filings, means the 60.3 score is derived from a near-complete data set, giving the scoring model high reliability for BSX specifically.
Why Not Higher
- The dividend sub-score of 0.0/20 and theme sub-score of 0.0/20 together contribute zero points to the model, representing 40 potential points that are entirely unrealized, which structurally caps the composite score well below 80.
- The profitability sub-score of 13.2/20 indicates that margin and return metrics reported in the filing fall short of the model's upper profitability thresholds, preventing what would otherwise be a materially higher composite score given the strong growth and momentum readings.
Data Confidence
9 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Boston Scientific Corporation is a global medical device manufacturer headquartered in Marlborough, Massachusetts, specializing in minimally invasive medical solutions across cardiology, electrophysiology, endoscopy, urology, and neuromodulation. Its product portfolio includes devices such as cardiac stents, pacemakers, electrophysiology mapping and ablation systems, endoscopic tools, and spinal cord stimulators, serving hospitals and healthcare systems worldwide. The company's FY 2025 10-K filing underpins a model score of 60.3/100, driven by notably strong momentum (18.0/20) and solid growth (17.5/20), reflecting consistent quarterly improvements in revenue and earnings reported in the filing. Profitability scored 13.2/20 and financial health 16.0/20, suggesting that while the balance sheet and interest coverage are manageable, operating margins and return on assets leave room for improvement relative to best-in-class medical device peers. The central research tradeoff for Boston Scientific is the tension between its high-momentum, high-growth operating profile and its relatively compressed profitability metrics alongside a complete absence of dividend income contribution (0.0/20). The aggressive growth goal profile scores 75.4 under the model, while the dividend income profile scores only 49.8, making clear that this is a reinvestment-oriented business rather than an income-generating one. Researchers oriented toward growth and operational momentum will find the filing data more compelling than those seeking income or near-term margin efficiency.
Plain English
Boston Scientific makes medical devices like heart stents, pacemakers, and minimally invasive surgical tools that doctors use in hospitals around the world. A model score of 60.3 out of 100 means the company shows real strengths in revenue growth and recent operational improvement, but it doesn't pay dividends and its profit margins aren't as strong as the very best in its industry. The Medium risk rating reflects that BSX operates in a competitive, highly regulated sector where growth execution is solid but profitability and debt levels require ongoing monitoring. It scores best as an aggressive growth research candidate, not as an income or low-risk holding.
Bull Case vs. Bear Case
Bull Case
- The momentum sub-score of 18.0/20 is the highest individual score in the model, indicating that Boston Scientific's most recent quarterly filings show consistent, sequential improvement in both revenue and earnings — a strong signal of operational traction.
- A growth sub-score of 17.5/20 reflects meaningful year-over-year expansion in revenue, net income, and EPS as reported in the FY 2025 10-K, suggesting the company's diversified device portfolio is gaining commercial scale.
- The financial health sub-score of 16.0/20 indicates that leverage and interest coverage ratios derived from the filing remain within a manageable range, supporting continued investment in R&D and potential acquisitions without immediate balance sheet distress.
Bear Case
- The profitability sub-score of 13.2/20 suggests that net margins, operating margins, and return on assets reported in the 10-K are below what the model recognizes as best-in-class for the medical device sector, limiting overall score upside.
- The dividend sub-score of 0.0/20 confirms Boston Scientific pays no dividend and has no dividend coverage metrics, making it unsuitable as a research candidate for income-oriented or yield-focused strategies.
- The theme sub-score of 0.0/20 indicates that the model did not map Boston Scientific's filing disclosures to any of the tracked macro thematic exposures, which reduces its composite score and limits appeal in thematic investment frameworks.
What Could Change the Picture
Bullish Triggers
- Sustained improvement in net margin and operating margin across future 10-K filings would lift the profitability sub-score from 13.2 toward 16 or higher, which could push the composite model score meaningfully above 65.
- If future EDGAR filings demonstrate Boston Scientific's revenue streams aligning with tracked macro themes — such as aging population healthcare infrastructure or robotic-assisted surgery — the theme sub-score could move from 0.0 to a meaningful positive, materially improving the overall score.
Bearish Triggers
- A deterioration in the quarterly revenue or earnings trajectory in upcoming filings would directly compress the momentum sub-score from its current 18.0/20, which is the single largest contributor to the current score, weakening the research case significantly.
- Any increase in leverage ratios or decline in interest coverage as reported in future 10-K filings — for example following a large debt-financed acquisition — would reduce the financial health sub-score below its current 16.0, adding to downside risk in the model.
Red Flags
- The profitability sub-score of 13.2/20, the weakest dimension aside from the zero-scoring categories, suggests that despite strong revenue growth, Boston Scientific's net and operating margins as filed have not yet scaled proportionally, which warrants monitoring across future filings.
- A financial health sub-score of 16.0/20, while adequate, combined with an aggressive acquisition history in the medical device space, means leverage ratios should be tracked closely in subsequent 10-K filings for any deterioration.
Risk Profile
Medium RiskThe Medium risk rating for Boston Scientific reflects a company that demonstrates strong top-line growth and operational momentum from filing data, but operates in a heavily regulated, litigation-exposed medical device environment where margin pressure, acquisition integration risk, and balance sheet leverage are ongoing concerns. The absence of dividend income and relatively modest profitability metrics mean the risk-reward profile is tilted toward growth execution rather than capital preservation.
Key Catalysts to Watch
The key factors to monitor in future EDGAR filings are whether Boston Scientific's operating and net margins expand as revenue scales — which would directly improve the profitability sub-score — and whether the sequential quarterly momentum in revenue and earnings documented in the FY 2025 10-K is sustained or accelerates in upcoming reporting periods.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.